Clinical trial

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

NCT07084610

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-02-25

PhasePHASE2

Study timeline

Study start (actual)2025-02-25Date precision: day

Registry last updated2026-09-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancerunresolved

Interventions

Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant)DRUG

Sponsors & collaborators

Hospital das Clínicas de Ribeirão Pretolead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07084610 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.